{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:25:57Z","timestamp":1764318357129,"version":"3.46.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clim.2025.110633","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:16:59Z","timestamp":1761959819000},"page":"110633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-titer IVIG 10\u00a0% (human)\u2013slra reduces infections and hospitalizations over 6 to 12\u00a0months: A retrospective quality improvement study"],"prefix":"10.1016","volume":"282","author":[{"given":"Gabrielle Magdalena","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Sehmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hostoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110633_bb0005","unstructured":"ADMA Biologics. ASCENIV\u2122 (immune globulin intravenous, human \u2013 sira) [package insert]. US Food and Drug Administration website. Available from: https:\/\/www.fda.gov\/media\/122525\/download."},{"issue":"1","key":"10.1016\/j.clim.2025.110633_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/25785826.2022.2151170","article-title":"ASCENIV utilization in a primary immunodeficiency patient with recurrent viral infections","volume":"46","author":"Rosenbach","year":"2023","journal-title":"Immunol Med."},{"key":"10.1016\/j.clim.2025.110633_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110633_bb0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s10875-016-0308-z","article-title":"Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease","volume":"36","author":"Wasserman","year":"2016","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2025.110633_bb0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaip.2021.10.073","article-title":"Respiratory infections in patients with primary immunodeficiency","volume":"10","author":"Lehman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.clim.2025.110633_bb0035","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/v15071543","article-title":"Hyperimmune Globulins for the Management of Infectious Diseases","volume":"15","author":"Pati","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.clim.2025.110633_bb0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fimmu.2015.00431","article-title":"Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses","volume":"6","author":"Orange","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2025.110633_bb0045","first-page":"2","article-title":"Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction. Allergy asthma","volume":"21","author":"Mallick","year":"2025","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2025.110633_bb0050","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10875-022-01238-0","article-title":"Hematopoietic cell transplantation for adenosine deaminase severe combined immunodeficiency-improved outcomes in the modern era","volume":"42","author":"Ghimenton","year":"2022","journal-title":"J. Clin. Immunol."},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2025.110633_bb0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-024-00925-4","article-title":"Secondary Immunodeficiency","volume":"20","author":"Pourshahnazari","year":"2025","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110633_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70310","article-title":"Evidence- and consensus-based recommendations for the screening, diagnosis, and Management of Secondary Hypogammaglobulinemia in patients with systemic autoimmune rheumatic diseases by the Taiwan College of Rheumatology Experts","volume":"28","author":"Tsao","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2025.110633_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/curroncol30010022","article-title":"A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency","volume":"30","author":"Visentin","year":"2022","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.clim.2025.110633_bb0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2025.110633_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1399180","article-title":"Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report","volume":"15","author":"Billi","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2025.110633_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/vox.12246","article-title":"In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins","volume":"109","author":"Miescher","year":"2015","journal-title":"Vox Sang."},{"issue":"3","key":"10.1016\/j.clim.2025.110633_bb0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tmrv.2022.06.001","article-title":"ISBT COVID-19 convalescent plasma working group (see the appendix). Production and quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins against SARS-CoV-2","volume":"36","author":"Burnouf","year":"2022","journal-title":"Transfus. Med. Rev."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625002086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625002086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:21:28Z","timestamp":1764318088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625002086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["S1521661625002086"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110633","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-titer IVIG 10\u00a0% (human)\u2013slra reduces infections and hospitalizations over 6 to 12\u00a0months: A retrospective quality improvement study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110633"}}